

SELECTED REFERENCES

1. Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. *Annals of oncology*, 2017; 28(8):1713-29.
2. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. *European journal of cancer*, 2012; 48(10):1466-75.
3. Carillio G, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, Di Maio M, et al. Cetuximab in non-small-cell lung cancer. *Expert review of anticancer therapy*, 2012; 12(2):163-75.
4. Cervantes A, T M, E M, Rodriguez-Braun F, Ciardiello F, Stroh C, et al. Correlation of KRAS status (wild type vs. mutant) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 2008; 26(15S):4129.
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *New England Journal of Medicine*, 2004; 351(4):337-45.
6. De Roock W, Lambrechts D, Tejpar S. K-ras mutations and cetuximab in colorectal cancer. *New England Journal of Medicine*, 2009; 360(8):834-6.
7. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. *Annals of Oncology*, 2008; (3):508-15.
8. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. *British Journal of Cancer*, 2007; 96(8):1166-9.
9. Di Fiore F, Van Cutsem E, Laurent-Puig P, S S, Frattini M, De Roock W, et al. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series. *Journal of clinical oncology*, 2008; 26(May 20 Suppl.): 4035.
10. Douillard JY, Pirker R, O'Byrne KJ, Kerr KM, Storkel S, von Heydebreck A, et al. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. *Journal of thoracic oncology*, 2014; 9(5): 717-24.
11. Ettinger DS. Emerging profile of cetuximab in non-small cell lung cancer. *Lung cancer (Amsterdam, Netherlands)*. 2010; 68(3): 332-7.
12. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, et al. Cetuximab and irinotecan 5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. *Annals of Oncology*, 2006; 17(3):450-6.
13. Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. *The Lancet Oncology*, 2011; 12(1):30-7.
14. Herbst RS, Hirsch FR. Patient selection criteria and the FLEX Study. *Lancet (London, England)*. 2009;373(9674):1497-8.
15. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *European journal of cancer*, 2017; 70: 87-98.

16. Kohne CH, Poston G, Folprecht G, Ciardiello F, Ronga P, Beier F, et al. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study. *European journal of surgical oncology*, 2016; 42(10): 1540-7.
17. Kohne CH, Rougier P, Stroh C, Schlichting M, Bokemeyer C, Van Cutsem E. Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: A meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. *ASCO Gastrointestinal Cancers Symposium 2010*. Abstract 406.
18. Kohne CH, Van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer. Results of EORTC GI Group Study 40986. *Proc Am Soc Clin Oncol* 2003. 2003;22. Abstract 1018.
19. Ku GY, Haaland BA, de Lima Lopes G, Jr. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. *Cancer chemotherapy and pharmacology*, 2012; 70(2): 231-8.
20. Lang I, Kohne CH, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, et al. Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients with K-Ras wild type tumors in the CRYSTAL trial. *European Journal of Cancer*, 2009; Suppl Vol 7 (No.2, Sept 2009): 345.
21. Lang I, Kohne CH, Folprecht G, Rougier P, Curran D, Hitre E, et al. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. *European journal of cancer*, 2013; 49(2): 439-48.
22. Langer CJ. Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. *Clinical lung cancer*, 2008; 9(5): 249-51.
23. Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. *European journal of cancer*, 2013; 49(6): 1161-8.
24. O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. *The Lancet Oncology*, 2011; 12(8): 795-805.
25. Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. *Journal of clinical oncology*, 2013; 31(30): 3764-75.
26. Pirker R, Filipits M. Cetuximab in non-small-cell lung cancer. *Translational lung cancer research*, 2012; 1(1):54-60.
27. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. *Lung cancer*, 2012; 77(2):376-82.
28. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet*, 2009; 373(9674): 1525-31.
29. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. *The Lancet Oncology*, 2012; 13(1): 33-42.
30. Raoul JL, Van Laethem JL, Peeters M, Brezault C, Hussein F, Cals L, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. *BMC cancer*, 2009; 9:112.

31. Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. *Oncology*, 2009; 77 Suppl 1: 57-68.
32. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. *Oncologist*, 2001; 6(1):81-91.
33. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. *Journal of Clinical Oncology*, 2004; 22(7): 1201-8.
34. Saltz LB, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). *Journal of clinical oncology*, 2001; *Proc Am Soc Clin Oncol* 20. Abstract 7.
35. Schimanski CC, Staib F, Gohler T, Hebart H, Heike M, Neise M, et al. Dermatum: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. *Journal of cancer research and clinical oncology*, 2017; 143(6): 1023-34.
36. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. *Journal of clinical oncology*, 2012; 30(29): 3570-7.
37. Tejpar S, De Roock W, Biesmans B, De Schutter J, Piessevaux H, Humblet Y, et al. High amphiregulin and epiregulin expression in KRAS wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. *Journal of clinical oncology*, 2008; 26(May 20 Suppl): 411.
38. Tejpar S, Peeters M, Humblet Y, Gelderblom J, Vermoken JB, Viret F, et al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data. *Journal of clinical oncology*, 2006; *ASCO Annual Meeting Proceedings Part I. Vol 24 (18S (June 20 Suppl.))*: 3554.
39. Tejpar S, Peeters M, Humblet Y, Gelderblom J, Vermoken JB, Viret F, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. *Journal of clinical oncology*, 2007; *ASCO Annual Meeting Proceedings Part I. Vol 25 (18S (June 20 Suppl.))*: 4037.
40. Tejpar S, Peeters M, Humblet Y, Vermoken JB, De Hertogh G, De Roock W, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). *Journal of clinical oncology*, 2008; 26(May 20 suppl.): 4001.
41. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JGJ, Verslype C, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. *The Lancet Oncology*, 2007; 8(5): 387-94.
42. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. *JAMA oncology*. 2016.
43. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *New England Journal of Medicine*, 2009; 360(14): 1408-17.
44. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *Journal of clinical oncology*, 2011; 29(15): 2011-9.

45. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. *Journal of Clinical Oncology*, 2008; 26 (May 20 Suppl, A2).
46. Van Cutsem E, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer – the influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. *ASCO Gastrointestinal Cancers Symposium 2010*; Abstract 281.
47. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *Journal of clinical oncology*, 2015; 33(7):692-700.
48. Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. [Review]. *European Journal of Cancer* 42 (14):2212-21, 2006.
49. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *Journal of Clinical Oncology*, 2007; 25(13):1658-64.
50. Van Cutsem E, Pozzo C, Starkhammar H, Dirix L, Terzoli E, Cognetti F, et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. *Annals of Oncology*, 1998; (11):1199-204.
51. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, M.A., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. *Annals of Oncology*, 2009; 20(11): 1842-7.
52. Van Cutsem E, Rougier P, Kohne CH, Stroh C, Schlichting M, Bokemeyer C. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy as 1st line treatment for patients with metastatic colorectal cancer: Results according to K-RAS and BRAF mutation status. *European Journal of Cancer*, 2009; Suppl. Vol. 7 (No 2 Sept 2009): 345.
53. Windsor AC, Cohen R, Jiao LR, Stebbing J. Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear. *Future oncology*, 2008; 4(6):741-4.